Tim Nestler

University Hospital Cologne

Papers

1

Total Citations

15

H-Index

1

About

Dr. Tim Nestler is a leading urologic oncologist whose research focuses on optimizing treatment strategies for testicular cancer, particularly seminoma. His major contributions center on reducing long-term treatment toxicity while maintaining excellent oncologic outcomes. Dr. Nestler is best known for his work on nerve-sparing retroperitoneal lymph node dissection (RPLND) in clinical stage IIA/B seminoma, as demonstrated by the landmark COTRIMS trial. This study, which has garnered 15 citations, challenges the standard use of chemotherapy or radiation by offering a surgical alternative that preserves nerve function and reduces morbidity. The trial addresses a critical gap in seminoma management, where traditional therapies achieve high cure rates (90–94% for stage IIA, 82–90% for stage IIB) but carry significant risks of secondary malignancies, cardiovascular disease, and infertility. By pioneering minimally invasive surgical techniques, Dr. Nestler has expanded treatment options for young patients, prioritizing quality of life without compromising survival. His work represents a paradigm shift toward personalized, risk-adapted care in testicular cancer, earning him recognition as a key figure in advancing urologic oncology and improving outcomes for this curable malignancy.

Research Focus

Key Achievements

1
H-Index
1
Papers
15
Total Citations
15
Avg Citations/Paper
🏆 Most Cited Paper
Nerve sparing retroperitoneal lymph node dissection in clinical stage IIA/B seminoma: The COTRIMS trial.
15 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 3
🏛 Institutions: University Hospital Cologne

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago